A meta-analysis across patients with 27 types or subtypes of tumors showed that the tumor mutational burden (TMB) is correlated with the response rate following anti-PD-1 or anti-PD-L1 therapy [29]. The gene discussed is PDCD1; the disease is neoplasm.